RANBP1, a member of the nuclear-cytoplasmic trafficking-regulator complex, is the terminal-striking point of the SGK1-dependent Th17+ pathological differentiation.

Carolina Brescia, Vincenzo Dattilo, Lucia D'Antona, Emanuela Chiarella, Rossana Tallerico, Salvatore Audia, Valentina Rocca, Rodolfo Iuliano, Francesco Trapasso, Nicola Perrotti, Rosario Amato

Frontiers in immunology 2023

filter terms:

The Th17+ arrangement is critical for orchestrating both innate and acquired immune responses. In this context, the serum and glucocorticoid regulated kinase 1 (SGK1) exerts a key role in the governance of IL-23R-dependent Th17+ maturation, through the phosphorylation-dependent control of FOXO1 localization. Our previous work has shown that some of the SGK1-key functions are dependent on RAN-binding protein 1 (RANBP1), a terminal gene in the nuclear transport regulation. Here, we show that RANBP1, similarly to SGK1, is modulated during Th17+ differentiation and that RANBP1 fluctuations mediate the SGK1-dependent effects on Th17+ maturation. RANBP1, as the final effector of the SGK1 pathway, affects FOXO1 transport from the nucleus to the cytoplasm, thus enabling RORγt activation. In this light, RANBP1 represents the missing piece, in an essential and rate-limiting manner, underlying the Th17+ immune asset. Copyright © 2023 Brescia, Dattilo, D’Antona, Chiarella, Tallerico, Audia, Rocca, Iuliano, Trapasso, Perrotti and Amato.

Citation

Carolina Brescia, Vincenzo Dattilo, Lucia D'Antona, Emanuela Chiarella, Rossana Tallerico, Salvatore Audia, Valentina Rocca, Rodolfo Iuliano, Francesco Trapasso, Nicola Perrotti, Rosario Amato. RANBP1, a member of the nuclear-cytoplasmic trafficking-regulator complex, is the terminal-striking point of the SGK1-dependent Th17+ pathological differentiation. Frontiers in immunology. 2023;14:1213805